Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05953610 · ClinicalTrials.gov registry record · Phase 2

Endotypic Traits and Obstructive Sleep Apnea Surgery

A Phase 2 study of Obstructive Sleep Apnea, sponsored by University of California, Los Angeles.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
2
Study locations

NCT05953610 is a Phase 2 study of Obstructive Sleep Apnea that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 150 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (32% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05953610, a Phase 2 study of Obstructive Sleep Apnea, is actively recruiting participants, sponsored by University of California, Los Angeles.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
2
Study locations

Study Summary

This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).

Conditions Studied

Interventions

  • DRUG Acetazolamide 500 MG QHS
  • DRUG Eszopiclone 3 mg QHS

Study Locations (2)

California

  • UCLA Santa Monica Medical Center - Santa Monica
  • UCLA Westwood - Westwood, Los Angeles

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-01-07
Est. Completion 2028-08-31
Phase Phase 2

What the Registry Record Tells You About NCT05953610

The ClinicalTrials.gov registry entry for NCT05953610 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (32% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 2 interventions - of which Acetazolamide 500 MG QHS is the first listed.

NCT05953610 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05953610 about?

NCT05953610 is a clinical study titled "Endotypic Traits and Obstructive Sleep Apnea Surgery". This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).

What is the current status of trial NCT05953610?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-01-07. Estimated completion is 2028-08-31.

What conditions does trial NCT05953610 study?

This clinical trial studies the following conditions: Obstructive Sleep Apnea.

What interventions are being tested in trial NCT05953610?

The interventions under investigation include: Acetazolamide 500 MG QHS (DRUG), Eszopiclone 3 mg QHS (DRUG).

Who is sponsoring clinical trial NCT05953610?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05953610 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obstructive Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.